These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7817846)

  • 21. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electroconvulsive therapy for a patient with persistent tardive dyskinesia: a case report and literature review.
    Peng LY; Lee Y; Lin PY
    J ECT; 2013 Sep; 29(3):e52-4. PubMed ID: 23965612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double blind controlled study of ECT vs chlorpromazine in schizophrenia.
    Bagadia VN; Abhyankar RR; Doshi J; Pradhan PV; Shah LP
    J Assoc Physicians India; 1983 Oct; 31(10):637-40. PubMed ID: 6671932
    [No Abstract]   [Full Text] [Related]  

  • 24. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?
    Crow TJ; Cross AJ; Johnstone EC; Owen F; Owens DG; Waddington JL
    J Clin Psychopharmacol; 1982 Oct; 2(5):336-40. PubMed ID: 7130435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
    Langlois-Thery S; Dollfus S; Lesieur P; Petit M
    Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involuntary disorders of movement in chronic schizophrenia--the role of the illness and its treatment.
    Owens DG
    Psychopharmacology Suppl; 1985; 2():79-87. PubMed ID: 2860663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
    Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
    Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tardive dyskinesia and glucid metabolism.
    Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
    Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
    Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
    Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients.
    Cassady SL; Thaker GK; Tamminga CA
    Psychopharmacol Bull; 1993; 29(2):235-40. PubMed ID: 8290671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study.
    Tuason VB; Escobar JI; Garvey M; Schiele B
    J Clin Psychiatry; 1984 Apr; 45(4):158-63. PubMed ID: 6370967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skin conductance responding in schizophrenic patients with abnormal involuntary movements.
    Mintz M; Alfisi S; Sigal M
    Psychiatry Res; 1990 Oct; 34(1):19-27. PubMed ID: 1980017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases.
    Chouinard G; Sultan S
    Psychopharmacol Bull; 1990; 26(3):337-41. PubMed ID: 2274634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defect symptoms and abnormal involuntary movement in schizophrenia.
    Iager AC; Kirch DG; Jeste DV; Wyatt RJ
    Biol Psychiatry; 1986 Jul; 21(8-9):751-5. PubMed ID: 2873845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients.
    Tetreault L; Bordeleau JM; Gauthier R; Vulpe M; Lapointe L
    Dis Nerv Syst; 1969 Feb; 30(2):Suppl:74-84. PubMed ID: 4886994
    [No Abstract]   [Full Text] [Related]  

  • 38. A double-blind comparison of pimozide and chlorpromazine in the maintenance care of chronic schizophrenic outpatients.
    Kolivakis T; Azim H; Kingstone E
    Curr Ther Res Clin Exp; 1974 Sep; 16(9):998-1004. PubMed ID: 4214674
    [No Abstract]   [Full Text] [Related]  

  • 39. Loxapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients.
    Steinbook RM; Goldstein BJ; Brauzer B; Moreno SS; Jacobson AF
    Curr Ther Res Clin Exp; 1973 Jan; 15(1):1-7. PubMed ID: 4631378
    [No Abstract]   [Full Text] [Related]  

  • 40. Alpha methyldopa-chlorpromazine interaction in schizophrenic patients.
    Chouinard G; Pinard G; Prenoveau Y; Tetreault L
    Curr Ther Res Clin Exp; 1973 Feb; 15(2):60-72. PubMed ID: 4632508
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.